This talk was presented at the 2018 SAGES Meeting/16th World Congress of Endoscopic Surgery by Tommy A Brown during the MS03: Full-Day Military Surgical Symposium – General Surgery Presentations on April 11 2018
Keyword(s): breast cancer, cardiac toxicity, chemotherapy, complication, demographics, E75, ejection fraction, GM-CSF, HER2, HLA-A2, immunogenic, immunomodulating stimulant, interim analysis, intradermal, lymphocytes, monoclonal antibody, neo-adjuvant therapy, overexpressing, peptide vaccine, phase II trial, prevention, prospective randomized trial, radiation, recurrence, safety, standard of care, trastuzumab
Keyword(s): breast cancer, cardiac toxicity, chemotherapy, complication, demographics, E75, ejection fraction, GM-CSF, HER2, HLA-A2, immunogenic, immunomodulating stimulant, interim analysis, intradermal, lymphocytes, monoclonal antibody, neo-adjuvant therapy, overexpressing, peptide vaccine, phase II trial, prevention, prospective randomized trial, radiation, recurrence, safety, standard of care, trastuzumab